ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunolo... (American rights to nasal dosage forms of...)

HOME >> MEDICINE >> TECHNOLOGY

ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

Date:11/9/2009

American rights to nasal dosage forms of bepotastine from Tanabe Seiyaku and obtained a future right to negotiate for a North American license to oral dosage forms of bepotastine for allergy treatment.

Full prescribing information for Bepreve(TM) is available on ISTA Pharmaceuticals' website at http://www.istavision.com/pdf/Bepreve_insert.pdf.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is the fourth largest branded ophthalmic pharmaceutical business in the U.S. ISTA's four marketed products plus its product candidates include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company is developing a strong product pipeline to fuel future growth and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5%, Xibrom(TM) (bromfenac ophthalmic solution) 0.09%, and Istalol® (timolol maleate ophthalmic solution) 0.5% are trademarks of ISTA Pharmaceuticals.

SOURCE ISTA Pharmaceuticals, Inc.

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
2. DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
4. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
5. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
6. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
11. VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009

Post Your Comments:

(Date:11/20/2009)...Nov. 20 Unilens Vision I...ge: UVI), which develops, licenses, manufactures, ...today reported its operating results for the first...Net sales excluding royalty income, were $1,683,67...61,526 reported in the previous year first quarter...

(Date:11/20/2009)...Nov. 20 Cornerstone Ther...ceutical company focused on acquiring, developing ... for the respiratory and related markets, today re...the Food and Drug Administration ("FDA") alleging ...ne HCl 10 mg, Pyrilamine Maleate 16 mg) and Decons...

(Date:11/20/2009)...Ky., Nov. 20 The National Associ...y announced a new initiative in the war on methamp...LEx) is a multi-state electronic tracking program ...nter (OTC) medicines containing pseudoephedrine in...or NPLEx is based on a system that was developed a...

Breaking Medicine Technology:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 2 Unilens Vision Reports Record First Quarter Earnings and Royalty Income 3 Unilens Vision Reports Record First Quarter Earnings and Royalty Income 4 Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 2 Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 3 National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production 2 National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production 3 Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays 3F ECRI Institute outlines best practices to ensure bette 5783 1 Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays 3F ECRI Institute outlines best practices to ensure bette 5783 2 Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays 3F ECRI Institute outlines best practices to ensure bette 5783 3 2009 Annual Meetings emphasize sustainability 10554 1 2009 Annual Meetings emphasize sustainability 10554 2 Let Kids Sleep Late on Weekends to Fight Fat 3A Study 60231 1 Let Kids Sleep Late on Weekends to Fight Fat 3A Study 60231 2 Let Kids Sleep Late on Weekends to Fight Fat 3A Study 60231 3

[0] Unilens Vision Reports Record First Quarter Earnings and Royalty Income [0] Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal [0] National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production

...HIA, March 4 Premier Research Group Limited, the ...eased to announce its role in the submission of th...l/niacin) Tablets for the sponsor, Acura Pharmaceu...nical trial management for the pivotal Phase 3 cli...ed at their research centers, as well as provided ...

...PLETE RESPONSE RATE , , - MEDIAN SURVIVAL OF 10.5...ARGETED FOR 2009 ASH ANNUAL MEETING , , SOUTH SAN...daq: HNAB ) today announced new positive prelimi...sis of the ongoing pivotal rALLy clinical trial ev... injection) for the treatment of adult acute lymph...

Other Medicine Technology:Premier Research Announces Milestone New Drug Application 2 Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 2 Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 3 Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 4 Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 5

Premier Research Announces Milestone New Drug Application Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia

(Date:11/20/2009)... Senators and Congressmen in Competitive Re-elec... Care Vote , Washington, ...essmen running for re-election next year in races ... Cook, may come to regret voting for House Speaker...to a breaking Zogby International/ O’Leary R...

(Date:11/20/2009)...N.J., Nov. 20 Rates of i... peaked in late October, but the pandemic flu viru... all age groups, including the elderly, according ...(NYSE: DGX ), the world,s leading provider of di... In its most recent Quest Diagnostics Health Trend...

(Date:11/20/2009).... 20 The American Denta...Drug Administration (FDA) to establish appropriate..., Citing concern about the safety of whitening ...enefit of professional consultation or examination...cation of chemically based tooth whitening or blea...

(Date:11/20/2009)..., Nov. 20 Centene Corp...l present at the Bank of America Merrill Lynch 200..., at the Crowne Plaza Hotel Times Square in New Yo...ember 2nd at 8:30 a.m. Eastern Time. Investors and... webcast of Centene,s presentation at: http://www...

(Date:11/20/2009)..., Israel, November 20 Ca...p://www.CVSLMEDICAL.COM , a leading,developer of a...nnounced that,the company,s Board of Directors has..., Canada and the Far East for its proprietary next...ll angioplasty (PCTA) procedures. , Cardi...

Breaking Medicine News(10 mins):Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2 Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3 Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2 Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3 Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2 Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2

[0] Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill [0] H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics [0] American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products [0] Centene Corporation to Present at Bank of America Merrill Lynch Credit Conference [0] Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East

... Most Interesting Metabolic Projects,Available for...aera,Corporation (NASDAQ: GENR ) will present at ...erence being held November 3-5 at the Lowes Hotel ...eatment of type 2 diabetes and obesity on Tuesday,...

...ley,Corporation (Nasdaq: QGLY ), http://www.quig...g operations of $6.4 million, for the third quarte...on reported for the third quarter,ended September ...ember 30, 2007., The third quarter and nine month...

...ellmark Inc.,(Nasdaq: ORCH ), a leading worldwide...reported its financial results for the third quart...r the third quarter of 2008,compared to $15.6 mill...es in the U.K., Total U.S.-based revenues rose by...

...mber 6, 2008 at 1:30 p.m. (Pacific); ... , SAN DIEGO, Oct. 30 ADVENTRX Pharmaceuticals,I...t a conference call with,simultaneous webcast to d...t and Chief Financial Officer, is scheduled,to lea...

...e Survey Places Company Seventh in Atlanta Busines... Alpharetta, Ga. (Vocus) October 30, 2008-- Atlant... (JH) one of "Atlanta,s Best Places to Work&... 20 medium-size companies (101-500 employees), acc...

...by SEIU,Secretary-Treasurer Anna Burger on Barack ... moment. In six days, voters will head to the poll...r rescuing our nation from,the biggest economic cr...e class, affordable,healthcare for all, a real sol...

Genaera to Present at Therapeutic Area Partnerships 2008 The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future Orchid Cellmark Reports Third Quarter 2008 Financial Results ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results Jackson Healthcare Is Named Among "Atlanta's Best Places to Work"Obama Puts Healthcare, Economic Relief for Middle Class First in Prime-Time Special

Colorcard® Streptozyme® Streptococcal Antibody Test

Virogen® Rotatest® Rotavirus Test

Mono-Test® Mononucleosis Test

...sional Diagnostics is a leading provider of immuno... test menu that includes kits for autoimmune disea...llaneous conjugates and components. Our Impact IFA...ates and kit sizes to choose from. Kit components ...

Medicine Products:

Colorcard® Streptozyme® Streptococcal Antibody Test Virogen® Rotatest® Rotavirus Test Mono-Test® Mononucleosis Test Toxoplasma gondii (Toxo) Antibody IgM

ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunolo...(American rights to nasal dosage forms of...),Health